Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.
Volume: 39, Issue: 15_suppl, Pages: 4511 - 4511
Published: May 20, 2021
Abstract
4511 Background: Savolitinib is a potent and selective MET inhibitor with activity in MET-driven papillary renal cancer (PRC). Durvalumab is a PD-L1 inhibitor which has been tested in combination with savolitinib in metastatic PRC with response rates of 29% (12/41). Here we describe the efficacy of this combination in MET-driven metastatic PRC. Methods: This single arm phase I/II trial explored durvalumab (1500mg Q4W) and savolitinib (600mg OD)...
Paper Details
Title
Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.
Published Date
May 20, 2021
Journal
Volume
39
Issue
15_suppl
Pages
4511 - 4511
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History